Getting Started With Medicinal Cannabis In Australia
Medicinal cannabis isn't a cure-all you can just walk into a shop and buy. The Australian system is bureaucratic, expensive, and frustrating if you don't know the pathways. I've helped people navigate this over the years, and the single biggest mistake I see is assuming this works like a standard PBS prescription. It doesn't. Most medicinal cannabis products aren't on the PBS unless you qualify for a very narrow set of exemptions. The legal pathway runs through TGA approval, not your GP alone. Your doctor needs to apply to the Therapeutic Goods Administration under the Special Access Scheme or Authorised Prescriber pathway. The TGA assesses whether the benefit to the patient outweighs the risks, then grants approval. After that, you still need a state or territory health authority to issue a import permit before the medication can actually reach you. That's two separate government approvals before anyone writes a script. I had a patient with treatment-resistant neuropathic pain who came to me after six months of waiting. His GP had submitted the SAS application and then... nothing. The form was incomplete. He'd ticked the wrong box for indication, selecting general pain management rather than the specific neuropathic pain category. The TGA rejected it outright. We resubmitted with the correct indication code, added a letter from his neurologist confirming prior failed treatments, and got approval within three weeks. The original rejection took six months of silence to resolve because there's no automatic status check on the TGA portal unless you've set up notifications.
Once approved, the prescribing doctor orders from a licensed supplier. AVIC is the main one, but there are several other approved suppliers now. The medication ships from Sydney or Melbourne depending on the supplier. Turnaround is typically five to fourteen business days after the order is placed.
What The Products Actually Look Like
Most prescribed products are CBD-dominant oils, sometimes with low THC levels. Sativex is a buccal spray containing equal parts CBD and THC, available on the PBS for spasticity in multiple sclerosis. That's essentially the only medicinal cannabis product on the PBS right now. Everything else is private prescription and costs anywhere from $60 to $200 per month depending on the formulation and dose. There are also dried flower products for vaporisation, tablets, and sublingual sprays. The THC content matters more than people realise. Low-THC products (less than 1%) tend to be better tolerated for chronic conditions. Higher-THC formulations carry significant side effect risk including cognitive impairment, anxiety, and dependency concerns. Start low and go slow is the standard clinical advice, but "start low" for cannabis means starting at 2.5mg of THC or less and titrating up by 2.5mg weekly. That's a much slower escalation schedule than most patients expect.
Get the Full Details
Common Conditions And What The Evidence Actually Says
Chronic pain is the most common reason people pursue this. The evidence here is moderate. Some patients get meaningful relief, others don't. The Australian Medical Association acknowledges that the quality of evidence across pain conditions is generally low to moderate, with significant heterogeneity in study design. Neuropathic pain has slightly better evidence than nociceptive pain. Spasticity from MS has the strongest evidence base. Sativex is PBS-listed for this for good reason. Epilepsy, particularly treatment-resistant forms like Dravet syndrome, also has solid evidence. Anxiety and PTSD are commonly cited but the evidence is weaker and these are off-label uses that require more justification on the SAS application. What nobody tells you: insomnia is probably the one condition where patients report the most satisfaction, but that's largely because THC has sedative properties. It's not treating the underlying sleep disorder. Long-term use for insomnia creates tolerance and dependency. I've seen patients who started on 5mg THC at night and were working their way up to 40mg within six months. That's not sustainable and it masks whatever's actually causing the sleep problem.
Costs And Practical Barriers
Even with private health insurance covering some of it, most patients pay out of pocket. A typical CBD oil prescription might run $80-$120 per month. Sativex on the PBS costs the standard PBS co-payment, but you still need the neurologist or specialist to maintain the prescription. The initial SAS application process itself is free but it takes time from your doctor, and not all GPs are willing to invest that time without specialist support letters already in place. The biggest practical barrier I encounter is continuity of supply. There have been multiple occasions where suppliers ran out of particular formulations due to manufacturing issues or demand spikes. When that happens, patients get switched to an equivalent product, which means re-titration from scratch. Losing three weeks of dose stability because a supplier couldn't keep up is genuinely disruptive for someone managing a chronic condition.
Working Around The System
If you're pursuing this, come to your doctor's appointment prepared. Have a written summary of your condition, all prior treatments attempted with outcomes, and any relevant specialist reports. The SAS application requires detailed clinical justification. Doctors who receive well-prepared patients submit stronger applications first time around. Consider seeing a specialist rather than relying solely on your GP. Neurologists, palliative care physicians, and pain specialists have more experience with medicinal cannabis applications and understand the TGA requirements better. A specialist-led application has a higher success rate and tends to move through the system faster because the clinical documentation is more thorough. Keep records of everything. Every approval letter, every prescription, every delivery. If there's a supply disruption or your supplier changes formulations, having your complete history makes switching between products significantly easier. I had a patient lose three months of progress because he couldn't reconstruct his dosing history after changing doctors. The new prescriber had no idea what worked and what didn't.
